"Detection, Quantification And/Or Isolation Of Circulating Tumor Cells Based On The Expression Of Cd321 Marker" in Patent Application Approval Process (USPTO 20250027946).

A patent application by inventors BLANPAIN, Cedric, PASTUSHENKO, Ievgenia, and SOTIROPOULOU, Panagiota focuses on detecting, quantifying, and isolating circulating tumor cells (CTCs) based on the expression of the CD321 marker. The invention aims to provide alternative and improved methods for characterizing, diagnosing, and monitoring neoplastic diseases in subjects. CD321 is identified as a more reliable and sensitive marker for cancer cells and CTCs compared to conventional markers like EpCAM and Keratin-14, offering potential benefits for cancer disease management and therapy. [Extracted from the article]